Treatment of Chronic Obstructive Pulmonary Disease (Copd) and Anti-Inflammatory DiseasesTechnology #ua15-181
Questions about this technology? Ask a Technology Manager
Title: Treatment of Toll-Like Receptor-Mediated Inflammation
Invention: This invention is a chronic obstructive pulmonary disease (COPD) treatment that inhibits signaling of Toll-Like Receptors which cause inflammation in the lungs. The drug mimics the action of an anti-inflammatory glycoprotein by recreating a peptide sequence in the protein and directing it into the affected cells. The drug can then have the anti-inflammatory effect of the protein without the cytotoxic effects.
Background: MUC1 is a glycoprotein with anti-inflammatory activity in mucosal epithelial cells, with the anti-inflammatory effect resulting from a particular peptide sequence within the protein. That peptide sequence, along with two carrier molecules, was found by the inventors to have anti-inflammatory effects in mice with COPD-like inflammation.
- Commercial; pharmaceutical
- Research; pharmaceutical
- Treats early stages of pulmonary inflammation before chronic inflammation can develop instead of treating incurable chronic inflammation
- Small molecule with highly specific activity
- Mimics the function of a naturally occurring protein
- Does not have the cytotoxic effects associated with increased concentration of the natural protein